Therapeutic antibody targeting of individual Notch receptors

By Yan Wu, Carol Cain-Hom, L. Choy, Thijs J. Hagenbeek, G. D. Leon, Yongmei Chen, D. Finkle, Rayna Venook, Xiumin Wu, J. Ridgway and 14 more. Nature, 2010

718 citations recorded by the source corpus.

Subfields: Molecular Biology, Small Animals

View Paper: https://www.semanticscholar.org/paper/2d596abd6e1221776e1edfd43e12f742c1be2f80

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Capobianco
2. Kelly L. Weaver
3. Prathibha Ranganathan

Citations in the corpus

• Notch signalling in solid tumours: a little bit of everything but not all the time (2011, background): “Furthermore, several novel biological agents (such as, antibodies and decoys) are being developed to inhibit Notch signallin”
• Beyond natural antibodies: the power of in vitro display technologies (2011, background): “3d ), preventing the proteolytic cleavage and translocation of the intracellular domai”
• Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways (2011, background): “Selective inhibition of Notch receptors reduce intestinal toxic effects in rodent xenograft models and may hold promise in future clinical development”
• Mesoporous silica nanoparticles in medicine--recent advances. (2013, background): “This has spurred the development of not only small molecular drugs such as GSIs but also therapeutic antibodies [59] and peptides [60] several of which are in clinical trials.”
• Inflammation and atherosclerosis: signaling pathways and therapeutic intervention (2022, background): “Animal studies show that mAbs targeting individual Notch ligands or receptors exert reduced intestinal toxicity, compared with that found by GSI treatment.(258,259) Additional experimental data show the potential of targeting Notch pathway in atherosclerosis treatment.”